Registered Cardiovascular Invasive Specialist (RCIS) Practice Test

ReoPro is primarily associated with which type of receptors?

1. IIb/IIIa receptors

2. Factor Xa receptors

3. Thrombin receptors

4. Adhesion receptors

The correct answer is: IIb/IIIa receptors

ReoPro, also known as abciximab, is a monoclonal antibody that primarily targets the glycoprotein IIb/IIIa receptor on the surface of platelets. This receptor plays a crucial role in platelet aggregation and is essential for the final common pathway of platelet activation. By binding to these receptors, ReoPro effectively blocks the binding of fibrinogen and other adhesive molecules, which prevents platelet aggregation and formation of blood clots. The significance of targeting IIb/IIIa receptors relates to the management of conditions like acute coronary syndrome and during percutaneous coronary interventions (PCI), where the prevention of thrombus formation is critical. ReoPro is utilized in these situations to decrease the risk of complications associated with clot formation, thereby improving patient outcomes. Other options such as Factor Xa receptors, thrombin receptors, and adhesion receptors pertain to different pathways in hemostasis and thrombosis but are not the direct targets of ReoPro, which specifically interacts with the IIb/IIIa receptor complex. This distinction underscores the specificity of ReoPro's action in the therapeutic context of antiplatelet treatment.